| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Pressure | 99 | 2024 | 317 | 15.430 |
Why?
|
| Hypertension | 67 | 2023 | 419 | 11.430 |
Why?
|
| Hypertrophy, Left Ventricular | 40 | 2021 | 65 | 10.200 |
Why?
|
| Ventricular Function, Left | 39 | 2021 | 80 | 7.360 |
Why?
|
| Heart Ventricles | 37 | 2021 | 60 | 7.270 |
Why?
|
| Ventricular Remodeling | 30 | 2021 | 44 | 7.220 |
Why?
|
| Aorta | 27 | 2024 | 43 | 7.170 |
Why?
|
| Pulse Wave Analysis | 35 | 2025 | 61 | 6.920 |
Why?
|
| Arterial Pressure | 20 | 2022 | 35 | 6.830 |
Why?
|
| Vascular Stiffness | 22 | 2024 | 41 | 6.050 |
Why?
|
| Ventricular Dysfunction, Left | 23 | 2020 | 47 | 5.720 |
Why?
|
| Middle Aged | 134 | 2025 | 3601 | 4.960 |
Why?
|
| Male | 172 | 2025 | 6754 | 4.500 |
Why?
|
| Hemodynamics | 22 | 2022 | 32 | 3.760 |
Why?
|
| Adult | 97 | 2025 | 5913 | 3.590 |
Why?
|
| Female | 136 | 2025 | 9103 | 3.410 |
Why?
|
| Humans | 157 | 2025 | 14537 | 3.410 |
Why?
|
| Obesity | 21 | 2020 | 367 | 3.250 |
Why?
|
| Arthritis, Rheumatoid | 32 | 2019 | 158 | 3.110 |
Why?
|
| Cardiovascular Diseases | 21 | 2024 | 237 | 3.080 |
Why?
|
| Diastole | 29 | 2021 | 43 | 3.070 |
Why?
|
| Aged | 55 | 2024 | 1740 | 2.890 |
Why?
|
| Adrenergic beta-Agonists | 17 | 2018 | 25 | 2.880 |
Why?
|
| Carotid Intima-Media Thickness | 23 | 2025 | 108 | 2.840 |
Why?
|
| Brachial Artery | 14 | 2021 | 29 | 2.780 |
Why?
|
| Echocardiography | 37 | 2021 | 100 | 2.730 |
Why?
|
| Isoproterenol | 19 | 2018 | 20 | 2.640 |
Why?
|
| Myocardium | 28 | 2020 | 35 | 2.630 |
Why?
|
| Stroke Volume | 15 | 2021 | 43 | 2.440 |
Why?
|
| Cardiomyopathy, Dilated | 14 | 2013 | 35 | 2.370 |
Why?
|
| Heart | 19 | 2024 | 27 | 2.240 |
Why?
|
| Heart Rate | 12 | 2024 | 32 | 2.110 |
Why?
|
| Glomerular Filtration Rate | 15 | 2021 | 62 | 2.070 |
Why?
|
| Risk Factors | 49 | 2024 | 1475 | 2.050 |
Why?
|
| Carotid Artery Diseases | 13 | 2024 | 34 | 2.050 |
Why?
|
| Resistin | 7 | 2020 | 10 | 1.980 |
Why?
|
| Systole | 25 | 2021 | 37 | 1.940 |
Why?
|
| Insulin Resistance | 11 | 2020 | 79 | 1.930 |
Why?
|
| Vascular Resistance | 7 | 2021 | 12 | 1.930 |
Why?
|
| Myocardial Contraction | 22 | 2010 | 23 | 1.920 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 12 | 2017 | 27 | 1.820 |
Why?
|
| Rats | 48 | 2020 | 130 | 1.820 |
Why?
|
| Sodium | 7 | 2021 | 30 | 1.800 |
Why?
|
| Animals | 50 | 2020 | 1081 | 1.630 |
Why?
|
| Potassium | 5 | 2020 | 25 | 1.550 |
Why?
|
| Aging | 7 | 2020 | 109 | 1.540 |
Why?
|
| Atherosclerosis | 16 | 2025 | 100 | 1.510 |
Why?
|
| Adiposity | 10 | 2020 | 96 | 1.500 |
Why?
|
| Predictive Value of Tests | 15 | 2024 | 188 | 1.500 |
Why?
|
| Arteries | 9 | 2024 | 18 | 1.430 |
Why?
|
| Angiotensinogen | 8 | 2018 | 15 | 1.430 |
Why?
|
| Age Factors | 14 | 2024 | 370 | 1.410 |
Why?
|
| Manometry | 9 | 2018 | 12 | 1.310 |
Why?
|
| Stroke | 7 | 2025 | 62 | 1.300 |
Why?
|
| Renin-Angiotensin System | 8 | 2020 | 12 | 1.300 |
Why?
|
| Kidney | 4 | 2020 | 46 | 1.220 |
Why?
|
| Heart Failure | 6 | 2021 | 38 | 1.210 |
Why?
|
| Blood Pressure Determination | 8 | 2018 | 27 | 1.200 |
Why?
|
| Receptors, Adrenergic, beta | 6 | 2018 | 6 | 1.190 |
Why?
|
| Myocytes, Cardiac | 6 | 2016 | 8 | 1.190 |
Why?
|
| Sodium Chloride, Dietary | 6 | 2020 | 27 | 1.150 |
Why?
|
| Exercise | 4 | 2016 | 205 | 1.140 |
Why?
|
| Young Adult | 18 | 2020 | 2498 | 1.140 |
Why?
|
| Rats, Sprague-Dawley | 33 | 2020 | 63 | 1.140 |
Why?
|
| Cross-Sectional Studies | 25 | 2025 | 1422 | 1.130 |
Why?
|
| Antihypertensive Agents | 11 | 2020 | 64 | 1.090 |
Why?
|
| Circadian Rhythm | 7 | 2018 | 31 | 1.060 |
Why?
|
| South Africa | 45 | 2025 | 7596 | 1.040 |
Why?
|
| Overweight | 4 | 2020 | 87 | 1.040 |
Why?
|
| Biomarkers | 17 | 2020 | 327 | 1.040 |
Why?
|
| Collagen | 15 | 2020 | 23 | 1.030 |
Why?
|
| Inflammation | 7 | 2020 | 104 | 1.010 |
Why?
|
| Carotid Artery, Common | 1 | 2024 | 6 | 0.940 |
Why?
|
| Body Mass Index | 17 | 2018 | 321 | 0.920 |
Why?
|
| Organ Size | 20 | 2017 | 34 | 0.910 |
Why?
|
| Risk Assessment | 12 | 2024 | 225 | 0.910 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2022 | 3 | 0.880 |
Why?
|
| Rats, Inbred SHR | 16 | 2018 | 17 | 0.870 |
Why?
|
| Cytokines | 5 | 2019 | 107 | 0.860 |
Why?
|
| Ventricular Pressure | 3 | 2018 | 5 | 0.830 |
Why?
|
| Sex Characteristics | 3 | 2017 | 43 | 0.830 |
Why?
|
| Heart Failure, Diastolic | 2 | 2020 | 2 | 0.830 |
Why?
|
| C-Reactive Protein | 9 | 2020 | 96 | 0.810 |
Why?
|
| Cardiomegaly | 6 | 2009 | 8 | 0.800 |
Why?
|
| Polymorphism, Genetic | 7 | 2008 | 99 | 0.780 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 30 | 0.750 |
Why?
|
| Sex Factors | 8 | 2024 | 227 | 0.720 |
Why?
|
| Heart Diseases | 2 | 2018 | 19 | 0.720 |
Why?
|
| Rats, Inbred WKY | 16 | 2018 | 17 | 0.710 |
Why?
|
| Blood Flow Velocity | 9 | 2018 | 17 | 0.710 |
Why?
|
| Cardiovascular Agents | 4 | 2016 | 11 | 0.700 |
Why?
|
| Electric Impedance | 1 | 2020 | 8 | 0.690 |
Why?
|
| Arteriosclerosis | 1 | 2020 | 24 | 0.690 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 9 | 2008 | 29 | 0.690 |
Why?
|
| Aldosterone | 5 | 2014 | 12 | 0.670 |
Why?
|
| African Americans | 4 | 2020 | 47 | 0.670 |
Why?
|
| Echocardiography, Doppler | 6 | 2021 | 18 | 0.670 |
Why?
|
| Kidney Diseases | 1 | 2020 | 38 | 0.670 |
Why?
|
| Time Factors | 11 | 2019 | 507 | 0.650 |
Why?
|
| Plaque, Atherosclerotic | 6 | 2019 | 27 | 0.640 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2021 | 69 | 0.640 |
Why?
|
| Norepinephrine | 10 | 2008 | 13 | 0.630 |
Why?
|
| Phosphodiesterase Inhibitors | 4 | 2005 | 10 | 0.630 |
Why?
|
| Regression Analysis | 14 | 2017 | 133 | 0.620 |
Why?
|
| Signal Transduction | 1 | 2018 | 33 | 0.620 |
Why?
|
| Ischemia | 4 | 2020 | 19 | 0.610 |
Why?
|
| Pulsatile Flow | 8 | 2017 | 14 | 0.610 |
Why?
|
| Kidney Glomerulus | 2 | 2020 | 5 | 0.600 |
Why?
|
| Receptors, Adrenergic, beta-2 | 3 | 2006 | 5 | 0.600 |
Why?
|
| Prognosis | 7 | 2021 | 199 | 0.600 |
Why?
|
| Neurotensin | 3 | 2006 | 3 | 0.590 |
Why?
|
| Receptors, Adrenergic, beta-1 | 2 | 2008 | 2 | 0.590 |
Why?
|
| Castration | 1 | 2017 | 1 | 0.580 |
Why?
|
| Telomere | 5 | 2016 | 17 | 0.580 |
Why?
|
| Disease Models, Animal | 14 | 2018 | 45 | 0.560 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2014 | 7 | 0.560 |
Why?
|
| Residence Characteristics | 2 | 2016 | 57 | 0.550 |
Why?
|
| Adrenergic Agents | 1 | 2016 | 1 | 0.550 |
Why?
|
| Pentoxifylline | 6 | 2005 | 13 | 0.540 |
Why?
|
| Cardiotonic Agents | 6 | 2008 | 8 | 0.530 |
Why?
|
| Radial Artery | 3 | 2012 | 4 | 0.510 |
Why?
|
| Heart Failure, Systolic | 1 | 2015 | 2 | 0.500 |
Why?
|
| Telomere Homeostasis | 4 | 2016 | 5 | 0.490 |
Why?
|
| Diabetes Mellitus | 6 | 2020 | 146 | 0.490 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 11 | 0.480 |
Why?
|
| Body Weight | 13 | 2020 | 111 | 0.480 |
Why?
|
| Physical Conditioning, Animal | 4 | 2000 | 4 | 0.480 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 2 | 2008 | 2 | 0.470 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2020 | 44 | 0.470 |
Why?
|
| Anabolic Agents | 3 | 2000 | 4 | 0.470 |
Why?
|
| Severity of Illness Index | 13 | 2018 | 253 | 0.460 |
Why?
|
| Endothelium, Vascular | 5 | 2019 | 29 | 0.460 |
Why?
|
| Adiponectin | 5 | 2016 | 15 | 0.460 |
Why?
|
| Waist Circumference | 6 | 2016 | 60 | 0.450 |
Why?
|
| Physical Education and Training | 1 | 2013 | 1 | 0.440 |
Why?
|
| Dyslipidemias | 2 | 2024 | 57 | 0.440 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 370 | 0.430 |
Why?
|
| Renin | 6 | 2018 | 10 | 0.420 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 2 | 2010 | 2 | 0.420 |
Why?
|
| Spironolactone | 2 | 2010 | 2 | 0.420 |
Why?
|
| Electrocardiography | 5 | 2016 | 35 | 0.420 |
Why?
|
| Apoptosis | 6 | 2015 | 40 | 0.410 |
Why?
|
| Prevalence | 11 | 2020 | 1192 | 0.410 |
Why?
|
| Publishing | 1 | 2012 | 5 | 0.410 |
Why?
|
| Genotype | 10 | 2011 | 442 | 0.390 |
Why?
|
| Ventricular Dysfunction | 1 | 2011 | 1 | 0.390 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 6 | 2019 | 25 | 0.390 |
Why?
|
| Hypertension, Renal | 1 | 2011 | 2 | 0.390 |
Why?
|
| Research | 1 | 2012 | 65 | 0.390 |
Why?
|
| Physical Endurance | 1 | 2011 | 3 | 0.390 |
Why?
|
| Bicycling | 1 | 2011 | 6 | 0.390 |
Why?
|
| Smoking | 3 | 2011 | 100 | 0.380 |
Why?
|
| Case-Control Studies | 11 | 2019 | 480 | 0.380 |
Why?
|
| Developed Countries | 1 | 2010 | 24 | 0.360 |
Why?
|
| In Vitro Techniques | 9 | 2006 | 54 | 0.360 |
Why?
|
| Sympathetic Nervous System | 3 | 2006 | 4 | 0.360 |
Why?
|
| Abdominal Fat | 2 | 2009 | 6 | 0.350 |
Why?
|
| Software | 4 | 2017 | 37 | 0.350 |
Why?
|
| Urban Health | 1 | 2010 | 78 | 0.350 |
Why?
|
| Random Allocation | 3 | 2016 | 23 | 0.350 |
Why?
|
| Longevity | 2 | 2020 | 14 | 0.350 |
Why?
|
| Prospective Studies | 10 | 2024 | 1160 | 0.350 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 468 | 0.350 |
Why?
|
| Arthritis, Experimental | 2 | 2020 | 2 | 0.340 |
Why?
|
| Leptin | 4 | 2014 | 26 | 0.340 |
Why?
|
| Creatinine | 6 | 2019 | 53 | 0.330 |
Why?
|
| Potassium, Dietary | 3 | 2018 | 5 | 0.320 |
Why?
|
| Carotid Arteries | 6 | 2018 | 19 | 0.320 |
Why?
|
| Nurses | 1 | 2009 | 32 | 0.310 |
Why?
|
| Adolescent | 8 | 2020 | 2985 | 0.310 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 171 | 0.310 |
Why?
|
| Surveys and Questionnaires | 5 | 2017 | 563 | 0.300 |
Why?
|
| Nandrolone | 2 | 2000 | 2 | 0.300 |
Why?
|
| Cardiomyopathies | 2 | 2004 | 15 | 0.280 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 1998 | 6 | 0.280 |
Why?
|
| Metabolic Syndrome | 5 | 2014 | 64 | 0.280 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 22 | 0.270 |
Why?
|
| Chemokine CCL2 | 4 | 2014 | 10 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2018 | 125 | 0.270 |
Why?
|
| Peripheral Arterial Disease | 2 | 2019 | 8 | 0.270 |
Why?
|
| Treatment Outcome | 8 | 2012 | 889 | 0.260 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 2 | 0.260 |
Why?
|
| Family | 2 | 2016 | 35 | 0.250 |
Why?
|
| Urban Population | 2 | 2011 | 257 | 0.250 |
Why?
|
| Peptidyl-Dipeptidase A | 5 | 2011 | 12 | 0.250 |
Why?
|
| Sampling Studies | 3 | 2015 | 13 | 0.240 |
Why?
|
| Retrospective Studies | 3 | 2014 | 799 | 0.230 |
Why?
|
| Diuretics | 5 | 2008 | 16 | 0.230 |
Why?
|
| Leukocytes | 3 | 2012 | 14 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2010 | 176 | 0.230 |
Why?
|
| Opportunistic Infections | 1 | 2024 | 10 | 0.220 |
Why?
|
| HIV Infections | 4 | 2025 | 5097 | 0.220 |
Why?
|
| Sodium Channels | 1 | 2003 | 6 | 0.220 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2024 | 33 | 0.220 |
Why?
|
| Ultrasonography | 7 | 2019 | 77 | 0.220 |
Why?
|
| Point Mutation | 1 | 2003 | 16 | 0.220 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2021 | 7 | 0.220 |
Why?
|
| Peptide Fragments | 3 | 2021 | 37 | 0.220 |
Why?
|
| Oxygen Consumption | 2 | 2013 | 15 | 0.220 |
Why?
|
| Femoral Artery | 3 | 2014 | 11 | 0.210 |
Why?
|
| Essential Hypertension | 1 | 2022 | 1 | 0.210 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 385 | 0.210 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2020 | 2 | 0.200 |
Why?
|
| Calcium | 4 | 2005 | 49 | 0.200 |
Why?
|
| Matrix Metalloproteinase 2 | 4 | 2018 | 11 | 0.190 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2014 | 20 | 0.190 |
Why?
|
| Dialysis | 1 | 2021 | 1 | 0.190 |
Why?
|
| Africa | 3 | 2012 | 376 | 0.190 |
Why?
|
| Renal Dialysis | 1 | 2021 | 27 | 0.190 |
Why?
|
| Apelin | 2 | 2018 | 3 | 0.190 |
Why?
|
| Asymptomatic Diseases | 2 | 2017 | 7 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 3 | 2018 | 18 | 0.180 |
Why?
|
| Organ Culture Techniques | 2 | 2017 | 6 | 0.170 |
Why?
|
| Extremities | 1 | 2020 | 5 | 0.170 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 4 | 0.170 |
Why?
|
| Recommended Dietary Allowances | 1 | 2020 | 11 | 0.170 |
Why?
|
| Testosterone Congeners | 1 | 2000 | 1 | 0.170 |
Why?
|
| Coronary Circulation | 4 | 2006 | 10 | 0.170 |
Why?
|
| Cells, Cultured | 3 | 2016 | 79 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 10 | 0.170 |
Why?
|
| Anthropometry | 2 | 2017 | 102 | 0.170 |
Why?
|
| Drug Therapy, Combination | 4 | 2008 | 279 | 0.170 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 1999 | 1 | 0.160 |
Why?
|
| Leg | 1 | 2019 | 21 | 0.160 |
Why?
|
| Digoxin | 3 | 2008 | 6 | 0.160 |
Why?
|
| ROC Curve | 5 | 2021 | 51 | 0.160 |
Why?
|
| Thrombosis | 1 | 2019 | 47 | 0.160 |
Why?
|
| Phenotype | 5 | 2006 | 158 | 0.160 |
Why?
|
| Rats, Inbred Dahl | 1 | 2018 | 1 | 0.160 |
Why?
|
| Electrolytes | 2 | 2010 | 5 | 0.160 |
Why?
|
| Hydroxyproline | 3 | 2006 | 3 | 0.150 |
Why?
|
| Mesenteric Arteries | 1 | 2018 | 1 | 0.150 |
Why?
|
| Vasoconstriction | 1 | 2018 | 2 | 0.150 |
Why?
|
| Glycated Hemoglobin A | 1 | 2018 | 24 | 0.150 |
Why?
|
| Regional Blood Flow | 2 | 2017 | 8 | 0.150 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 3 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2018 | 4 | 0.150 |
Why?
|
| Motor Activity | 1 | 1998 | 46 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 150 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 20 | 0.150 |
Why?
|
| Receptors, Neurotensin | 3 | 2006 | 3 | 0.150 |
Why?
|
| Pyrazoles | 3 | 2006 | 5 | 0.150 |
Why?
|
| Quinolines | 3 | 2006 | 14 | 0.150 |
Why?
|
| Insulin | 3 | 2020 | 73 | 0.150 |
Why?
|
| Myocardial Infarction | 2 | 2008 | 24 | 0.150 |
Why?
|
| Waist-Hip Ratio | 4 | 2012 | 29 | 0.150 |
Why?
|
| Cross-Linking Reagents | 1 | 1997 | 33 | 0.140 |
Why?
|
| Algorithms | 2 | 2015 | 106 | 0.140 |
Why?
|
| Interleukin-6 | 2 | 2016 | 51 | 0.140 |
Why?
|
| Renal Artery Obstruction | 2 | 1996 | 3 | 0.140 |
Why?
|
| Gene Frequency | 2 | 2008 | 122 | 0.140 |
Why?
|
| Endothelial Cells | 2 | 2015 | 14 | 0.140 |
Why?
|
| Perfusion | 4 | 2006 | 6 | 0.140 |
Why?
|
| Odds Ratio | 6 | 2019 | 133 | 0.140 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2016 | 5 | 0.140 |
Why?
|
| Adipokines | 2 | 2014 | 11 | 0.140 |
Why?
|
| Leukocyte Count | 2 | 2014 | 24 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2014 | 967 | 0.130 |
Why?
|
| Lectins | 1 | 2016 | 8 | 0.130 |
Why?
|
| Mathematical Concepts | 1 | 2016 | 1 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2016 | 2 | 0.130 |
Why?
|
| Guanidines | 1 | 1996 | 8 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2016 | 12 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 411 | 0.130 |
Why?
|
| Ethanol | 1 | 2015 | 3 | 0.130 |
Why?
|
| Calcium Channel Blockers | 2 | 2006 | 14 | 0.120 |
Why?
|
| Galectin 3 | 1 | 2015 | 2 | 0.120 |
Why?
|
| Elasticity | 3 | 2003 | 6 | 0.120 |
Why?
|
| Logistic Models | 6 | 2016 | 254 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 2 | 0.120 |
Why?
|
| Incidence | 2 | 2014 | 685 | 0.120 |
Why?
|
| Mortality | 1 | 2015 | 104 | 0.120 |
Why?
|
| Pedigree | 1 | 2014 | 30 | 0.120 |
Why?
|
| Adventitia | 1 | 2014 | 2 | 0.120 |
Why?
|
| Vasculitis | 1 | 2014 | 4 | 0.120 |
Why?
|
| Menopause | 1 | 2014 | 24 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2014 | 10 | 0.120 |
Why?
|
| Orchiectomy | 1 | 2014 | 6 | 0.120 |
Why?
|
| Chemokines | 1 | 2014 | 9 | 0.120 |
Why?
|
| Captopril | 3 | 2001 | 5 | 0.120 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2014 | 2 | 0.110 |
Why?
|
| Pulse | 2 | 2011 | 3 | 0.110 |
Why?
|
| Models, Biological | 2 | 2011 | 77 | 0.110 |
Why?
|
| Telomere Shortening | 1 | 2013 | 1 | 0.110 |
Why?
|
| White Coat Hypertension | 1 | 2013 | 2 | 0.110 |
Why?
|
| Nursing Staff | 1 | 2013 | 2 | 0.110 |
Why?
|
| Coronary Disease | 1 | 2013 | 17 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2014 | 30 | 0.110 |
Why?
|
| Hydrochlorothiazide | 1 | 1993 | 9 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 2 | 2004 | 23 | 0.110 |
Why?
|
| Lipids | 1 | 2013 | 81 | 0.110 |
Why?
|
| Cytochrome P-450 CYP11B2 | 2 | 2003 | 5 | 0.110 |
Why?
|
| Disease Progression | 3 | 2009 | 154 | 0.110 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2010 | 3 | 0.100 |
Why?
|
| Education, Professional, Retraining | 1 | 2012 | 1 | 0.100 |
Why?
|
| Financing, Government | 1 | 2012 | 11 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 10 | 0.100 |
Why?
|
| Necrosis | 3 | 2009 | 7 | 0.100 |
Why?
|
| Amino Acid Transport Systems | 1 | 2011 | 2 | 0.100 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2011 | 3 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 4 | 0.100 |
Why?
|
| Arginine | 1 | 2011 | 5 | 0.100 |
Why?
|
| Adenosine | 3 | 2001 | 6 | 0.100 |
Why?
|
| Blood Sedimentation | 3 | 2016 | 12 | 0.100 |
Why?
|
| Office Visits | 1 | 2011 | 6 | 0.090 |
Why?
|
| Compliance | 3 | 1996 | 3 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2011 | 16 | 0.090 |
Why?
|
| Linear Models | 3 | 2016 | 83 | 0.090 |
Why?
|
| Health Services | 1 | 2011 | 51 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 435 | 0.090 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2009 | 2 | 0.090 |
Why?
|
| Lithium | 2 | 2009 | 2 | 0.090 |
Why?
|
| Hypertension, Renovascular | 3 | 1996 | 4 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 25 | 0.090 |
Why?
|
| Depression | 1 | 2011 | 121 | 0.080 |
Why?
|
| Developing Countries | 4 | 2014 | 400 | 0.080 |
Why?
|
| E-Selectin | 3 | 2014 | 14 | 0.080 |
Why?
|
| Skinfold Thickness | 1 | 2009 | 6 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2016 | 20 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2006 | 22 | 0.080 |
Why?
|
| Solubility | 3 | 1998 | 51 | 0.080 |
Why?
|
| Private Sector | 1 | 2010 | 45 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2011 | 167 | 0.080 |
Why?
|
| Alleles | 2 | 2008 | 143 | 0.080 |
Why?
|
| Furosemide | 2 | 2006 | 3 | 0.080 |
Why?
|
| Public Sector | 1 | 2010 | 82 | 0.080 |
Why?
|
| National Health Programs | 1 | 2010 | 78 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2013 | 107 | 0.080 |
Why?
|
| Nephrons | 1 | 2009 | 2 | 0.080 |
Why?
|
| Auscultation | 1 | 2009 | 6 | 0.080 |
Why?
|
| Cyclic AMP | 2 | 2005 | 7 | 0.080 |
Why?
|
| Albuminuria | 1 | 2009 | 20 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2005 | 4 | 0.080 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 2 | 2005 | 2 | 0.080 |
Why?
|
| Health Surveys | 1 | 2008 | 59 | 0.080 |
Why?
|
| Genetics, Population | 1 | 2009 | 52 | 0.080 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 22 | 0.080 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2008 | 2 | 0.080 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2008 | 11 | 0.080 |
Why?
|
| Prediabetic State | 1 | 2008 | 3 | 0.080 |
Why?
|
| Homozygote | 1 | 2008 | 61 | 0.070 |
Why?
|
| Comorbidity | 3 | 2016 | 188 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2007 | 10 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 23 | 0.070 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2007 | 1 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 6 | 0.070 |
Why?
|
| Adrenergic Agonists | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cell Size | 1 | 2006 | 2 | 0.070 |
Why?
|
| Dobutamine | 1 | 2006 | 1 | 0.070 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2006 | 1 | 0.070 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2006 | 4 | 0.070 |
Why?
|
| Antirheumatic Agents | 3 | 2016 | 35 | 0.070 |
Why?
|
| Albuterol | 1 | 2006 | 6 | 0.070 |
Why?
|
| Species Specificity | 1 | 2006 | 49 | 0.070 |
Why?
|
| Blood Glucose | 2 | 2020 | 107 | 0.070 |
Why?
|
| Body Constitution | 2 | 2003 | 8 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2016 | 9 | 0.070 |
Why?
|
| Natriuresis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Awareness | 1 | 2006 | 18 | 0.070 |
Why?
|
| Nutrition Policy | 1 | 2006 | 19 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2006 | 64 | 0.070 |
Why?
|
| Sphygmomanometers | 1 | 2006 | 3 | 0.070 |
Why?
|
| HIV-1 | 1 | 2014 | 1260 | 0.070 |
Why?
|
| Haplotypes | 1 | 2006 | 125 | 0.060 |
Why?
|
| Extracellular Fluid | 1 | 2005 | 5 | 0.060 |
Why?
|
| Endotoxins | 1 | 2005 | 6 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 217 | 0.060 |
Why?
|
| Amrinone | 1 | 2005 | 1 | 0.060 |
Why?
|
| Rolipram | 1 | 2005 | 4 | 0.060 |
Why?
|
| Research Design | 1 | 2006 | 124 | 0.060 |
Why?
|
| Carbazoles | 1 | 2004 | 5 | 0.060 |
Why?
|
| Propanolamines | 1 | 2004 | 8 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2004 | 9 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2004 | 11 | 0.060 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 1996 | 2 | 0.060 |
Why?
|
| Amlodipine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Indapamide | 1 | 2004 | 4 | 0.060 |
Why?
|
| Perindopril | 1 | 2004 | 4 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2004 | 12 | 0.060 |
Why?
|
| Epithelial Sodium Channels | 1 | 2003 | 2 | 0.060 |
Why?
|
| Cholesterol, HDL | 2 | 2014 | 32 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 90 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 22 | 0.050 |
Why?
|
| Rats, Wistar | 2 | 2016 | 13 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 36 | 0.050 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 1 | 2002 | 2 | 0.050 |
Why?
|
| Hydralazine | 2 | 2001 | 3 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2014 | 23 | 0.050 |
Why?
|
| Protein Precursors | 1 | 2021 | 22 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2024 | 656 | 0.050 |
Why?
|
| Adrenergic Antagonists | 1 | 2001 | 1 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2001 | 2 | 0.050 |
Why?
|
| Aorta, Abdominal | 1 | 2001 | 4 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.050 |
Why?
|
| Phenylephrine | 2 | 2018 | 3 | 0.040 |
Why?
|
| Collagen Type II | 1 | 2020 | 1 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 9 | 0.040 |
Why?
|
| Cattle | 1 | 2020 | 28 | 0.040 |
Why?
|
| fas Receptor | 3 | 2004 | 13 | 0.040 |
Why?
|
| Mesylates | 1 | 1999 | 1 | 0.040 |
Why?
|
| Neprilysin | 1 | 1999 | 3 | 0.040 |
Why?
|
| Tyrosine | 1 | 1999 | 2 | 0.040 |
Why?
|
| Oxygenases | 1 | 1999 | 1 | 0.040 |
Why?
|
| Pertussis Toxin | 1 | 1999 | 2 | 0.040 |
Why?
|
| Xanthines | 1 | 1999 | 2 | 0.040 |
Why?
|
| Carotenoids | 1 | 1999 | 2 | 0.040 |
Why?
|
| Phenethylamines | 1 | 1999 | 2 | 0.040 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1999 | 3 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1999 | 1 | 0.040 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1999 | 1 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 44 | 0.040 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 12 | 0.040 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2018 | 1 | 0.040 |
Why?
|
| Androgens | 1 | 1998 | 5 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2018 | 6 | 0.040 |
Why?
|
| Steroids | 1 | 1998 | 14 | 0.040 |
Why?
|
| Absorption | 2 | 2009 | 6 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 40 | 0.040 |
Why?
|
| Rheumatoid Factor | 1 | 2018 | 16 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1997 | 5 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2004 | 272 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2016 | 4 | 0.030 |
Why?
|
| Fluorescence | 1 | 1996 | 9 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 5 | 0.030 |
Why?
|
| Action Potentials | 1 | 2016 | 2 | 0.030 |
Why?
|
| Streptozocin | 1 | 1996 | 2 | 0.030 |
Why?
|
| Isolated Heart Preparation | 1 | 2016 | 1 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2016 | 17 | 0.030 |
Why?
|
| Glucose | 1 | 2016 | 45 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 111 | 0.030 |
Why?
|
| Testosterone | 1 | 1995 | 14 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1995 | 3 | 0.030 |
Why?
|
| Dietary Fats | 1 | 1995 | 7 | 0.030 |
Why?
|
| Growth | 1 | 1995 | 14 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 1995 | 13 | 0.030 |
Why?
|
| Vasa Vasorum | 1 | 2014 | 2 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 1 | 0.030 |
Why?
|
| DNA | 1 | 2014 | 73 | 0.030 |
Why?
|
| Community Health Services | 1 | 2014 | 58 | 0.030 |
Why?
|
| Dilatation, Pathologic | 2 | 2004 | 2 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2013 | 14 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 43 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2013 | 13 | 0.030 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2013 | 3 | 0.030 |
Why?
|
| Dextrans | 1 | 1993 | 2 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 57 | 0.030 |
Why?
|
| Disease Management | 1 | 2013 | 74 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1992 | 2 | 0.030 |
Why?
|
| Angiotensin II | 1 | 1992 | 5 | 0.030 |
Why?
|
| Ethylmaleimide | 1 | 2011 | 2 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2011 | 3 | 0.020 |
Why?
|
| Leucine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Carboxylic Acids | 1 | 2011 | 3 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 65 | 0.020 |
Why?
|
| Indians, North American | 1 | 2011 | 2 | 0.020 |
Why?
|
| Posture | 1 | 2011 | 16 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2013 | 240 | 0.020 |
Why?
|
| Joints | 1 | 2010 | 9 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2010 | 30 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 1 | 0.020 |
Why?
|
| Eating | 1 | 2009 | 16 | 0.020 |
Why?
|
| Kidney Tubules, Distal | 1 | 2009 | 1 | 0.020 |
Why?
|
| Belgium | 1 | 2009 | 6 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2009 | 2 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 11 | 0.020 |
Why?
|
| Infliximab | 1 | 2008 | 2 | 0.020 |
Why?
|
| Triglycerides | 1 | 2008 | 47 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2008 | 4 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 89 | 0.020 |
Why?
|
| Cholesterol | 1 | 2008 | 38 | 0.020 |
Why?
|
| Glycolysis | 1 | 2008 | 2 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 107 | 0.020 |
Why?
|
| Ligation | 1 | 2007 | 2 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 16 | 0.020 |
Why?
|
| Methotrexate | 1 | 2007 | 17 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2007 | 12 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2007 | 1 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 142 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 109 | 0.020 |
Why?
|
| Neutrophils | 1 | 2007 | 53 | 0.020 |
Why?
|
| Atenolol | 1 | 2006 | 2 | 0.020 |
Why?
|
| Propranolol | 1 | 2006 | 2 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 64 | 0.020 |
Why?
|
| Lymphotoxin-alpha | 1 | 2005 | 2 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2005 | 24 | 0.020 |
Why?
|
| Remission Induction | 1 | 2005 | 6 | 0.020 |
Why?
|
| Losartan | 1 | 2005 | 2 | 0.020 |
Why?
|
| Transducers | 1 | 2004 | 1 | 0.010 |
Why?
|
| Exercise Test | 1 | 2004 | 13 | 0.010 |
Why?
|
| Outpatients | 1 | 2003 | 38 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 231 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2002 | 9 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 2002 | 2 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 156 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2002 | 40 | 0.010 |
Why?
|
| Purinergic P1 Receptor Agonists | 1 | 2001 | 1 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2001 | 1 | 0.010 |
Why?
|
| Inosine | 1 | 2001 | 2 | 0.010 |
Why?
|
| Caffeine | 1 | 2001 | 4 | 0.010 |
Why?
|
| Vasodilation | 1 | 2000 | 7 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 55 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 149 | 0.010 |
Why?
|
| Lisinopril | 1 | 1999 | 1 | 0.010 |
Why?
|
| Hormones | 1 | 1999 | 9 | 0.010 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 1999 | 3 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1999 | 3 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1999 | 8 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1999 | 11 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1999 | 1 | 0.010 |
Why?
|
| Forecasting | 1 | 1999 | 20 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1999 | 2 | 0.010 |
Why?
|
| Triazines | 1 | 1999 | 3 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1999 | 19 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1999 | 20 | 0.010 |
Why?
|
| Triazoles | 1 | 1999 | 20 | 0.010 |
Why?
|
| Survival Rate | 1 | 1999 | 96 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1998 | 6 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1998 | 13 | 0.010 |
Why?
|